Literature DB >> 21748432

CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC.

Erawan Borkham-Kamphorst1, Claudia R van Roeyen, Eddy Van de Leur, Jürgen Floege, Ralf Weiskirchen.   

Abstract

Nephroblastoma overexpressed gene encodes a matricellular protein (CCN3/NOV) of the CCN family, comprising CCN1 (CYR61), CCN2 (CTGF), CCN4 (WISP-1), CCN5 (WISP-2), and CCN6 (WISP-3). CCN proteins are involved in the regulation of mitosis, adhesion, apoptosis, extracellular matrix production, growth arrest and migration in multiple cell types. Compared to CCN2/CTGF, known as a profibrotic protein, the biological role of CCN3/NOV in liver fibrosis remains obscure. In this study we showed ccn3/nov mRNA to increase dramatically following hepatic stellate cell activation, reaching peak levels in fully transdifferentiated myofibroblasts. In models of experimental hepatic fibrosis, CCN3/NOV increased significantly at the mRNA and protein levels. CCN3/NOV was found mainly in non-parenchymal cells along the areas of tissue damage and repair. In the bile-duct ligation model, CCN3/NOV was localized mainly along portal tracts, while the repeated application of carbon tetrachloride resulted in CCN3/NOV expression mainly in the centrilobular areas. In contrast to CCN2/CTGF, the profibrotic cytokines platelet-derived growth factor-B and -D as well as transforming growth factor-β suppressed CCN3/NOV expression. In vitro, CCN3/NOV siRNA attenuated migration in the cirrhotic fat storing cell line CFSC well in line with in vivo findings that various types of cells expressing CCN3/NOV migrate into the area of tissue damage and regeneration. The suppression of CCN3/NOV enhanced expression of profibrotic marker proteins, such as α-smooth muscle actin, collagen type I, fibronectin, CCN2/CTGF and TIMP-1 in primary rat hepatic stellate cells and in CFSC. We further found that adenoviral overexpression of CCN2/CTGF suppressed CCN3/NOV expression, while the overexpression of CCN3/NOV as well as the suppression of CCN3/NOV by targeting siRNAs both resulted in enhanced CCN2/CTGF expression. These results indicate the complexity of CCN actions that are far beyond the classic Yin/Yang interplay.

Entities:  

Year:  2011        PMID: 21748432      PMCID: PMC3271194          DOI: 10.1007/s12079-011-0141-3

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  41 in total

1.  Inhibitory effect of soluble PDGF-beta receptor in culture-activated hepatic stellate cells.

Authors:  Erawan Borkham-Kamphorst; Doris Stoll; Axel M Gressner; Ralf Weiskirchen
Journal:  Biochem Biophys Res Commun       Date:  2004-04-30       Impact factor: 3.575

2.  Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis.

Authors:  Erawan Borkham-Kamphorst; Jens Herrmann; Doris Stoll; Jens Treptau; Axel M Gressner; Ralf Weiskirchen
Journal:  Lab Invest       Date:  2004-06       Impact factor: 5.662

3.  Antiproliferative activity of CCN3: involvement of the C-terminal module and post-translational regulation.

Authors:  A M Bleau; N Planque; N Lazar; D Zambelli; A Ori; T Quan; G Fisher; K Scotlandi; B Perbal
Journal:  J Cell Biochem       Date:  2007-08-15       Impact factor: 4.429

Review 4.  The modular architecture of a new family of growth regulators related to connective tissue growth factor.

Authors:  P Bork
Journal:  FEBS Lett       Date:  1993-07-26       Impact factor: 4.124

5.  CCN3/CCN2 regulation and the fibrosis of diabetic renal disease.

Authors:  Bruce L Riser; Feridoon Najmabadi; Bernard Perbal; Jo Ann Rambow; Melisa L Riser; Ernest Sukowski; Herman Yeger; Sarah C Riser; Darryl R Peterson
Journal:  J Cell Commun Signal       Date:  2010-02-09       Impact factor: 5.782

6.  Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells.

Authors:  M Pinzani; L Gesualdo; G M Sabbah; H E Abboud
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

7.  The expression of novH in adrenocortical cells is down-regulated by TGFbeta 1 through c-Jun in a Smad-independent manner.

Authors:  Jérôme Lafont; Maryvonne Laurent; Hélène Thibout; François Lallemand; Yves Le Bouc; Azeddine Atfi; Cécile Martinerie
Journal:  J Biol Chem       Date:  2002-07-30       Impact factor: 5.157

8.  Matricellular protein CCN3 (NOV) regulates actin cytoskeleton reorganization.

Authors:  Wun-Chey Sin; Mimi Tse; Nathalie Planque; Bernard Perbal; Paul D Lampe; Christian C Naus
Journal:  J Biol Chem       Date:  2009-08-25       Impact factor: 5.157

9.  Nephroblastoma overexpressed gene (NOV) expression in rat hepatic stellate cells.

Authors:  Sung Hee Lee; Geom Seog Seo; Young Nyun Park; Dong Hwan Sohn
Journal:  Biochem Pharmacol       Date:  2004-10-01       Impact factor: 5.858

10.  Regulation of CCN2 mRNA expression and promoter activity in activated hepatic stellate cells.

Authors:  Andrew Leask; Shaoqiong Chen; Daphne Pala; David R Brigstock
Journal:  J Cell Commun Signal       Date:  2008-09-17       Impact factor: 5.782

View more
  11 in total

1.  Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors:  Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal:  J Cell Commun Signal       Date:  2012-05-31       Impact factor: 5.782

Review 2.  The myofibroblast matrix: implications for tissue repair and fibrosis.

Authors:  Franco Klingberg; Boris Hinz; Eric S White
Journal:  J Pathol       Date:  2013-01       Impact factor: 7.996

3.  Anti-fibrotic effect of CCN3 accompanied by altered gene expression profile of the CCN family.

Authors:  Tarek Abd El Kader; Satoshi Kubota; Danilo Janune; Takashi Nishida; Takako Hattori; Eriko Aoyama; Bernard Perbal; Takuo Kuboki; Masaharu Takigawa
Journal:  J Cell Commun Signal       Date:  2012-10-14       Impact factor: 5.782

4.  Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer.

Authors:  Bruce L Riser; Jeffrey L Barnes; James Varani
Journal:  J Cell Commun Signal       Date:  2015-12-23       Impact factor: 5.782

Review 5.  Molecular and Genetic Interactions between CCN2 and CCN3 behind Their Yin-Yang Collaboration.

Authors:  Satoshi Kubota; Kazumi Kawata; Takako Hattori; Takashi Nishida
Journal:  Int J Mol Sci       Date:  2022-05-24       Impact factor: 6.208

6.  Myeloid deficiency of CCN3 exacerbates liver injury in a mouse model of nonalcoholic fatty liver disease.

Authors:  Wenconghui Wu; Xingjian Hu; Xianming Zhou; Philip A Klenotic; Qi Zhou; Zhiyong Lin
Journal:  J Cell Commun Signal       Date:  2017-12-06       Impact factor: 5.782

Review 7.  Hepatic stellate cells as key target in liver fibrosis.

Authors:  Takaaki Higashi; Scott L Friedman; Yujin Hoshida
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 17.873

8.  Blockade of CCN4 attenuates CCl4-induced liver fibrosis.

Authors:  Xiaofei Li; Yongxin Chen; Weiwei Ye; Xingfei Tao; Jinhong Zhu; Shuang Wu; Lianqing Lou
Journal:  Arch Med Sci       Date:  2015-06-19       Impact factor: 3.318

Review 9.  Liver Fibrosis-From Mechanisms of Injury to Modulation of Disease.

Authors:  Christian Liedtke; Yulia A Nevzorova; Tom Luedde; Henning Zimmermann; Daniela Kroy; Pavel Strnad; Marie-Luise Berres; Jürgen Bernhagen; Frank Tacke; Jacob Nattermann; Ulrich Spengler; Tilman Sauerbruch; Alexander Wree; Zeinab Abdullah; René H Tolba; Jonel Trebicka; Twan Lammers; Christian Trautwein; Ralf Weiskirchen
Journal:  Front Med (Lausanne)       Date:  2022-01-11

10.  Members of the Cyr61/CTGF/NOV Protein Family: Emerging Players in Hepatic Progenitor Cell Activation and Intrahepatic Cholangiocarcinoma.

Authors:  Qunfeng Wu; Marda Jorgensen; Joanna Song; Junmei Zhou; Chen Liu; Liya Pi
Journal:  Gastroenterol Res Pract       Date:  2016-10-18       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.